Diethylstilbestrol dipropionate
| Code | Size | Price |
|---|
| TAR-T31450-5mg | 5mg | £850.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
| TAR-T31450-50mg | 50mg | £1,661.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
| TAR-T31450-100mg | 100mg | £2,079.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
Diethylstilbestrol dipropionate can be used in estrogen therapy of relapsed prostate cancer.
CAS:
130-80-3
Formula:
C24H28O4
Molecular Weight:
380.484
Purity:
0.98
SMILES:
CCC(=O)Oc1ccc(cc1)C(CC)=C(/CC)c1ccc(OC(=O)CC)cc1
References
1. Hsieh TF, Tseng CJ, Tang JB, Chen YH. A proline rich acidic protein PRAP identified from uterine luminal fluid of estrous mice is able to enhance the estrogen responsiveness of Ishikawa cells. J Cell Biochem. 2011 Nov;112(11):3122-8. doi: 10.1002/jcb.23238. PubMed PMID: 21695714.
2. Nakata S, Miyazawa Y, Sasaki Y, Nakano K, Takahashi H. [Prognostic factors for estrogen therapy of relapsed prostate cancer after maximal androgen blockade (MAB)]. Nihon Hinyokika Gakkai Zasshi. 2010 May;101(4):597-602. Japanese. PubMed PMID: 20535987.
3. Fujinami K, Miura T, Takizawa A, Osada Y. [Combination chemotherapy with docetaxel and cisplatin in patients with hormone-refractory prostate cancer]. Hinyokika Kiyo. 2005 Jan;51(1):5-8. Japanese. PubMed PMID: 15732332.
4. Leaf AN, Propert K, Corcoran C, Catalano PJ, Trump DL, Harris JE, Davis TE. Phase III study of combined chemohormonal therapy in metastatic prostate cancer (ECOG 3882): an Eastern Cooperative Oncology Group study. Med Oncol. 2003;20(2):137-46. PubMed PMID: 12835516.